Publications and Presentations

Filter By:

Binimetinib and Encorafenib

09/12/2018

The Lancet Oncology

Overall Survival in Patients With BRAF-Mutant Melanoma Receiving Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib (COLUMBUS): a Multicentre, Open-Label, Randomised Phase 3 Trial

R. Dummer, M.D., et al.

Binimetinib and Encorafenib

06/23/2018

ESMO World Congress on Gastrointestinal Cancer

BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti–Epidermal Growth Factor Receptor Antibody Cetuximab for BRAFV600E Metastatic Colorectal Cancer

E. Van Cutsem, M.D., et al.

Binimetinib and Encorafenib

06/04/2018

ASCO Annual Meeting

Adverse Events of Special Interest in the Phase 3 COLUMBUS Study

Helen J. Gogas, M.D., et al.

Binimetinib and Encorafenib

06/04/2018

ASCO Annual Meeting

Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

R. Dummer, M.D., et al.

Binimetinib and Encorafenib

03/21/2018

The Lancet Oncology

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

R. Dummer, M.D., et al.

Binimetinib and Encorafenib

01/20/2018

2018 Gastrointestinal Cancers Symposium (ASCO GI)

BEACON CRC Study Safety Lead-in (SLI) in Patients With BRAFV600E Metastatic Colorectal Cancer (mCRC): Efficacy and Tumor Markers

E. Van Cutsem, et al.

Binimetinib

01/20/2018

2018 Gastrointestinal Cancers Symposium (ASCO GI)

Phase 1b/2 Study of Binimetinib in Combination With Nivolumab (NIVO) or NIVO Plus Ipilimumab in Patients With Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer With RAS Mutation

J. Bendell, et al.

ARRY-382

11/10/2017

Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

A phase 1b/2 dose-escalation study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF-1R) in combination with pembrolizumab for the treatment of patients with advanced solid tumors

Wael A. Harb, et al.

Binimetinib

09/10/2017

European Society for Medical Oncology Annual Congress

Quality of Life in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

H. J. Gogas, et al.

Binimetinib

09/10/2017

European Society for Medical Oncology Congress

Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

A. Arance, et al.